Drug Review: Terlipressin

International Journal of Pharmacology and Clinical Sciences, 2023, 12, 3, 138–139.
Published: February 2024
Type: Research Article
Authors: Juman Alsaab
 
Author(s) affiliations:

Juman Alsaab,
Pharm D Ministry of Health, Riyadh, SAUDI ARABIA.

Abstract

Registrations: It had been registered in the following countries: United Kingdom (UK), United States of America (USA), Canada, and Saudi Arabia (SA). Trade name (USA.); TERLIVAZ ® Registration number (SA); 11-367-07. Insurance Drug Formulary (SA); Covered. General Information: Registered Company: Mallinckrodt hospital products inc. Regulatory Status: RX. Mechanism of Action: Prodrug The active form is lysine vasopressin, the non-selective agonist of both V1 (smooth muscles of the arterial vasculature in the splanchnic region) and V2 receptors (collecting ducts of renal tubules). Read more…